The effect of adenosine A 2A receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2

Neurotoxicity Research

Volumn 22, Issue 2, 2012, Pages 150-157

  Gołembiowska, Krystyna ^a   Dziubina, Anna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adenosine A2A receptor antagonists; Oxidative stress; Parkinson's disease; VMAT2 function

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 (3 CHLOROSTYRYL)CAFFEINE; BENSERAZIDE; DOPAMINE; GLUTAMIC ACID; HYDROXYL RADICAL; LEVODOPA; RESERPINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG POTENTIATION; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; RADICAL REACTION; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ADENOSINE A2 RECEPTOR ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CAFFEINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; EXTRACELLULAR SPACE; GLUTAMIC ACID; HOMOVANILLIC ACID; HYDROXYL RADICAL; LEVODOPA; MALE; MICRODIALYSIS; OXIDATIVE STRESS; RATS; RATS, WISTAR; RESERPINE; TRIAZINES; TRIAZOLES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

RATTUS;

EID: 84865376975     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-012-9316-9     Document Type: Article

References (28)

1. Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine-or L-DOPA-induced neurotoxicity: the role of dopamine quinine formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5:165-176
2. Ascherio A, Zhang SH, Hernán MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001) Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50:56-63
3. Carlsson A, Lindqvist M, Magnusson T (1957) 3, 4-Dihydroxyphen-ylalanine and 5-hydroxytryptophan as reserpine antagonist. Nature 180:1200
4. 2A receptor antagonists. Neurology 61(6):S62-S68 (Pubitemid 37505550)
5. Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebroke RE, Di Monte DA, Emson PC, Miller GW (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27:8138-8148 (Pubitemid 47173329)
6. 2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and ''fine tuning'' modulation. Prog Neu-robiol 83:310-331 (Pubitemid 350119825)
7. Chen M-K, Kuwabara H, Zhou Y, Adams RJ, Brašić JR, McGloyhan JL, Verina T, Burton NC, Alexander M, Kumar A, Wong DF, Guilarte TR (2008) VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem 105:78-90 (Pubitemid 351441627)
8. Donzanti BA, Hite JF, Yamamoto BK (1993) Extracellular glutamate levels increase with age in the lateral striatum: potential involvement of presynaptic D-2 receptors. Synapse 13:376-382 (Pubitemid 23104543)
9. Ferré S, O'Connor WT, Fuxe K, Ungerstedt U (1993) The striopal-lidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci 13:5402-5406 (Pubitemid 24001022)
10. 2A receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats. Neurotox Res 21:222-230
11. 2A receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum. Neurotox Res 15:155-166
12. Halliwell B (2006) Oxidative stress and neurodegeneration: where we are now? J Neurochem 97:1634-1658 (Pubitemid 43873658)
13. 2A antagonists, and Parkinson's disease. Parkinsonism Rel Dis 15:406-413
14. Jonkers N, Sarre S, Ebinger G, Michotte Y (2002) MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res 926:149-155 (Pubitemid 34117600)
15. Knecht R, Chang JY (1986) Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino) azobenzenesulfonyl chloride. Anal Chem 58: 2375-2379
16. Meshul CK, Cogen JP, Cheng H-W, Moore C, Krentz L, McNeill TH (2000) Alterations in rat striatal glutamate synapses following a lesion of the cortico-and/or nigrostriatal pathway. Exp Neurol 165:191-206
17. Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey Al (1997) Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 41:530-539 (Pubitemid 27169193)
18. Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI (1999) Immunochemical analysis of vesicular mono-amine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 156:138-148 (Pubitemid 29152991)
19. Morari M, Marti M, Sbrenna K, Fuxe K, Bianchi C, Beani L (1998) Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochem Int 33:383-397 (Pubitemid 28559218)
20. 2A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications. Prog Neurobiol 83:293-309 (Pubitemid 350102747)
21. 2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine- lesioned rats: a micro-dialysis study. Neuroscience 100:53-62 (Pubitemid 30670301)
22. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, San Diego
23. Pollack AE, Fink JS (1995) Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 68:721-728
24. Popoli P, Blum D, Pintor A, Tebano MT, Frank C, Gianfriddo M, Domenici MR, Schiffmann SN, Pedata F (2004) The controversial role of adenosine receptor antagonists as neuroprotective agents. Curr Med Chem CNS Agents 4:35-45 (Pubitemid 38506332)
25. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung K-H, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674-2679 (Pubitemid 30337329)
26. 2A receptors in Parkinson's disease. Trends Neurosci 29:647-654 (Pubitemid 44602262)
27. 2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology 53:783-789 (Pubitemid 47542336)
28. 2A receptor antagonists in Parkinson's disease. Pharmacol Ther 105:267-310 (Pubitemid 40297894)